Meenhard Herlyn

Direct reprogramming of melanocytes to neural crest stem-like cells by one defined factor.

Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma.

Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a).

Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma.

Photocarcinogenesis in human adult skin grafts.

Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells.

Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction.

Melanoma-stroma interactions: structural and functional aspects.

Adenovirus-mediated ex vivo gene transfer of human vascular endothelial growth factor in a rabbit laryngotracheal reconstruction model.

Cyclin D1 is a candidate oncogene in cutaneous melanoma.

Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks.

Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.

p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma.

The Role of E-cadherin in the Motility and Invasion of Implantation Site Intermediate Trophoblast.

Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma.

New approaches to the biology of melanoma: a workshop of the National Institutes of Health Pathology B Study Section.

Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo.

BRAF and RAS mutations in human lung cancer and melanoma.

Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8.

Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis.

Melanoma development and progression: a conspiracy between tumor and host.

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.

Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice.

Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture.

p16INK4A and familial melanoma.

The vascular phenotype of melanoma metastasis.

Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil.

Tumors as elusive targets of T-cell-based active immunotherapy.

Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma.

High levels of CUG-initiated FGF-2 expression cause chromatin compaction, decreased cardiomyocyte mitosis, and cell death.

Slit-Robo: neuronal guides signal in tumor angiogenesis.

BRAF as a potential therapeutic target in melanoma and other malignancies.

Suppression of BRAF(V599E) in human melanoma abrogates transformation.

Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.

VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells.

Axis of evil: molecular mechanisms of cancer metastasis.

Reciprocal regulation of MelCAM and AKT in human melanoma.

The great escape: another way for melanoma to leave physiological control?

First international melanoma research congress.

Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3.

Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B.

Recent advances in melanoma biology.

Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis.

Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling.

Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells.

Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells.

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

Rapid apoptosis in the pulmonary vasculature distinguishes non-metastatic from metastatic melanoma cells.

The role of altered cell-cell communication in melanoma progression.

Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions.

Adenoviral mediated gene transfer of PDGF-B enhances wound healing in type I and type II diabetic wounds.

Cultivation of normal human epidermal melanocytes in the absence of phorbol esters.

Clinical protocol. Phase I trial to evaluate the safety of H5.020CMV.PDGF-b and limb compression bandage for the treatment of venous leg ulcer: trial A.

Gene expression profiling of melanoma cells - searching the haystack.

Functional erythropoietin autocrine loop in melanoma.

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture.

The prevalence of interferon-alpha transcription defects in malignant melanoma.

Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion.

Adhesion, migration and communication in melanocytes and melanoma.

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

Metastatic melanoma cells. Introduction.

Bone morphogenetic proteins in melanoma: angel or devil?

Information sharing and collateral damage.

Selective evolutionary pressure from the tissue microenvironment drives tumor progression.

A tumorigenic subpopulation with stem cell properties in melanomas.

Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression.

Molecular targets in melanoma: strategies and challenges for diagnosis and therapy.

[Melanoma-stroma interactions and melanoma progression].

Targeting the stromal fibroblasts: a novel approach to melanoma therapy.

Normal human melanocyte homeostasis as a paradigm for understanding melanoma.

Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics.

Expression of PKC isoforms in human melanocytic cells in situ.

Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1.

Defining the conditions for the generation of melanocytes from human embryonic stem cells.

Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.

Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.

Isolation of a novel population of multipotent adult stem cells from human hair follicles.

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.

A new organotypic model to study cell interactions in the intestinal mucosa.

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.

Embryogenesis meets tumorigenesis.

Differentiation of normal skin and melanoma using high resolution hyperspectral imaging.

Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo.

CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1.

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

Life isn't flat: taking cancer biology to the next dimension.

Microenvironmental influences in melanoma progression.

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells.

High-throughput oncogene mutation profiling in human cancer.

Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma.

Farming cells to rebuild skin and melanoma.

Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.

Rewired ERK-JNK signaling pathways in melanoma.

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.

Expression of integrin alpha10 is induced in malignant melanoma.

Association of polymorphisms of FAS-1377, FAS-670, and FASL-844 genes with risk factors for cutaneous malignant melanoma.

Old disease, new culprit: tumor stem cells in cancer.

Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells.

Unraveling mysteries of the multifunctional protein SPARC.

The many faces of Notch signaling in skin-derived cells.

The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation.

Roadmap for new opportunities in melanoma research.

Permissive environment in postnatal wounds induced by adenoviral-mediated overexpression of the anti-inflammatory cytokine interleukin-10 prevents scar formation.

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.

Microscale solution IEF combined with 2-D DIGE substantially enhances analysis depth of complex proteomes such as mammalian cell and tissue extracts.

Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status.

Modeling genomic diversity and tumor dependency in malignant melanoma.

The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Learning the ABCs of melanoma-initiating cells.

Salmonella typhimurium as a novel RNA interference vector for cancer gene therapy.

Similar biological activities of two isostructural ruthenium and osmium complexes.

The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis.

Unraveling the mysteries of IGF-1 signaling in melanoma.

Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.

Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.

Melanoma stem cells: the dark seed of melanoma.

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.

Melanoma and the tumor microenvironment.

Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Endothelin-3 stimulates survival of goblet cells in organotypic cultures of fetal human colonic epithelium.

Cleavage of MCM2 licensing protein fosters senescence in human keratinocytes.

A subpopulation of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification.

Cracking the system: melanoma complexity demands new therapeutic approaches.

Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy.

Cancer stem cells are everywhere.

Defining microenvironments within mouse models that enhance tumor aggressiveness.

Matricellular proteins produced by melanocytes and melanomas: in search for functions.

Driving in the melanoma landscape.

The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Active Notch1 confers a transformed phenotype to primary human melanocytes.

Placental gene transfer: transgene screening in mice for trophic effects on the placenta.

Distinct MHC gene expression patterns during progression of melanoma.

Embryonic stem cells as a model for studying melanocyte development.

Human dermal stem cells differentiate into functional epidermal melanocytes.

What is a good model for melanoma?

Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors.

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells.

Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer.

Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion.

The ups and downs of transcription factors in melanoma.

NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network.

BRAF inhibitor unveils its potential against advanced melanoma.

Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.

Boris Bastian.

A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling.

Taking the guesswork out of uveal melanoma.

A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling.

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Dermis-derived stem cells: a source of epidermal melanocytes and melanoma?

Targeting BRAF in advanced melanoma: a first step toward manageable disease.

Will engineered T cells expressing CD20 scFv eradicate Melanoma?

Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas.

From cancer stem cells to tumor maintenance in melanoma.

A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors.

Sorting through the many opportunities for melanoma therapy.

Organometallic Pyridylnaphthalimide Complexes as Protein Kinase Inhibitors.

Isolation and cultivation of dermal stem cells that differentiate into functional epidermal melanocytes.

Fibroblasts contribute to melanoma tumor growth and drug resistance.

The molecular pathology of cutaneous melanoma.

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options.

Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture.

MEK'ing the most of p53 reactivation therapy in melanoma.

A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles.

MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Acetylsalicylic Acid Governs the Effect of Sorafenib in -Mutant Cancers.

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma.

Distinct histone modifications denote early stress-induced drug tolerance in cancer.

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Endogenous authentic OCT4A proteins directly regulate FOS/AP-1 transcription in somatic cancer cells.

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival.

Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility.

Frontiers in pigment cell and melanoma research.

Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer.

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.

Loss of Phd2 cooperates with BRAF to drive melanomagenesis.

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.

Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.

Author Correction: Loss of Phd2 cooperates with BRAF to drive melanomagenesis.